Raily Aesthetic Medicine expects H1 profit attributable to shareholders of about RMB 4 million, swings from loss

• Raily Aesthetic Medicine guided for profit attributable to parent shareholders of about RMB 4 million for the six months ended June 30, 2026.
• That compares with a loss attributable to parent shareholders of about RMB 8 million a year earlier.
• Revenue is expected at about RMB 115 million versus about RMB 85 million a year earlier.
• The turnaround was linked to higher revenue, lifting gross profit by about RMB 15 million, driven by services growth, equipment product sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Raily Aesthetic Medicine International Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260807-12277754), on August 07, 2026, and is solely responsible for the information contained therein.